All In Biotech

Free tool

FAERS Monitor: Phendimetrazine Tartrate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018074 or its brand name (Phendimetrazine Tartrate, Phendimetrazine Tartrate). Reports on generic versions are filed under their own applications.

Reports

58

Serious

23

40% of reports

Hospitalization

8

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective9
  • pain7
  • headache6
  • weight increased6
  • back pain5
  • wrong technique in product usage process5
  • choroidal effusion4
  • dyspnoea4
  • fatigue4
  • myopia4
  • ocular hypertension4
  • off label use4
  • arthralgia3
  • fall3
  • hunger3

Reports by year received

View as table
YearReports
20071
20083
20101
20114
20121
20141
20155
20166
20172
20182
20197
20204
20212
20222
20235
20248
20253
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,101 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
choroidal effusionSignal41817.3704.15,531
ocular hypertensionSignal4748.8290.62,282
myopiaSignal4610.3236.91,859
hungerSignal378.125.9158
weight increasedSignal69.74.639
wrong technique in product usage processSignal58.93.928
back painSignal57.83.424
painSignal74.12.114
headacheSignal63.51.68
fall33.31.13
arthralgia32.60.92
dyspnoea42.61.02
drug ineffectiveSignal92.51.47
fatigue41.90.71
off label use41.70.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.